Vitamin K : this vitamin is essential for hepatic synthesis of clotting factor prothrombin.───维生素 K: 这是一种肝脏合成凝结因子凝血酉每元所必需的维生素. Hemophilia is a rare blood disorder, and people born with this condition have little or no clotting factor, a protein that controls bleedi...
into fibrin. Furthermore, thrombin amplifies its own generation by feedback activation offactors V, VIII and XI. Blood coagulation is controlled by several mechanisms, including the heparin–antithrombin interaction, thetissue factor pathway inhibitor(TFPI), activatedprotein Candfibrinolyticsystems[9–11]...
assay of clotting factors in plasma and emphasis on factor VIII:Cone-stage assay of factors VIII:C or IX:Clupus anticoagulant (LACone-stage assay componentsassay of clotting factorsfactor assays in presence of severe deficiencytwo-stage clotting assay for FVIII:C...
Factor Xa inhibitors are synthetic pentasaccharides that mediate the interaction of heparin with AT, thereby preventing the generation of thrombin.23,29 Fondaparinux (Arixtra) has been studied in patients undergoing elective hip and knee arthroplasty and hip fracture. It has a half-...
Recombinant clotting factor concentrates provide new opportunities for the treatment of hemostatic disorders such as haemophilia A and B and von Willebrand disease. This article briefly reviews the clinical results of currently available products, the development of concentrates of clotting factor IX and ...
Hemophilia is a congenital bleeding disorder caused by deficiency of clotting factor VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). Severe hemophilia patients have less than 1% (or 1 IU/dL) of normal factor activity, and often exp... A Mceneny-King 被引量: 0发表: 2020年 加载更...
Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated pla... We conclude that Stabilyte plasma is the specimen collection tube of choice for biobank projects aiming to measure fibrinolytic factors as ...
The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of
公开/公告日期: 1990年8月7日 发明人: ET Yin 被引量: 48 摘要: A composition, kit and method for determining the concentration of heparin in a blood plasma sample and a method for making the composition. The method includes incubating a blood plasma sample with a known amount of Factor X ...
Subsequent dosing of factor concentrate is based on the half-life of the specific concentrate. Both factors have an initial short half-life secondary to diffusion that becomes longer with repeat dosing. The initial half-life of FVIII is 6 to 8 hours, and the subsequent half-life is 8 to 12...